Key Findings
The study successfully validated a multi-omics approach for the simultaneous characterization of DNA and protein markers in CAR T-cell therapy. In CD22 CAR T-cell product samples (TR3 to TR7), the analysis identified measurable vector copy numbers, with the majority of transduced cells carrying between one and three vector copies per cell. Two-copy integrations represented the largest fraction across samples. Conversely, untransduced (UT) samples showed negligible copy numbers, with 97.9–100% of cells having zero vector reads.
Technical Details
The researchers used a targeted amplicon sequencing panel to evaluate total variants and vector-derived reads. Specificity was confirmed as an average of 99.89% (range: 99.83%–99.90%) of all vector-aligned reads mapped to 11 target regions (3 CAR1 amplicons and 8 vector amplicons). Reproducibility was high, with Spearman rho values between replicates ranging from a minimum of 0.97 to a median of 0.99.
Protein expression was analyzed using antibody oligonucleotide conjugates (AOC). The platform detected canonical T-cell markers including CD3, CD4, CD8, CD45RA, CD45RO, CD62L, CD27, CD183, and CD28. Analysis showed high concordance in marker read distributions between transduced and untransduced groups (Pearson r = 0.864, Spearman rho = 0.937), suggesting that lentiviral transduction did not substantially alter antibody capture efficiency.
Background and Context
The study analyzed apheresis products from five patients (four males, one female) aged five to 49 years, collected between March 2023 and July 2024. Four patients were diagnosed with Acute Lymphoblastic Leukemia (ALL) and one with Lymphoma. PBMCs were T-cell enriched, cultured, and transduced with a lentiviral vector encoding a CD22 CAR. To ensure accuracy, the researchers used UT cells as negative controls and a vector-transduced Jurkat cell line as a positive control.
Significance and Outlook
The integration of single-cell DNA and protein analysis allows for the precise estimation of VCN while simultaneously resolving T-cell subsets based on phenotype markers. This approach provides a more comprehensive characterization of the final CAR T-cell product compared to using ddPCR and flow cytometry separately.
Source: https://doi.org/10.21203/rs.3.rs-11529336/v1
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



